Inhibikase Therapeutics (IKT) Return on Sales (2020 - 2024)
Inhibikase Therapeutics (IKT) reported Return on Sales of 200639.37% for Q3 2024, down 20063877.0% year-over-year from N/an in Q4 2023, and down 8400106.04% quarter-over-quarter from 2.39% in Q2 2024.
Inhibikase Therapeutics (IKT) Return on Sales (2020 - 2024) Analysis & Trends
Inhibikase Therapeutics (IKT) has 5 years of Return on Sales data on file, last reported at 200639.37% in Q3 2024.
- Return on Sales for Q3 2024 came in at 200639.37%, down 20063877.0% year-over-year; the trailing twelve-month figure through Sep 2024 was 200639.37% (down 20063875.0% YoY), and the FY2023 annual result was 0.77%, up 70.0% from the prior year.
- Return on Sales slipped to 200639.37% in Q3 2024 per IKT's latest filing, from 2.39% in the prior quarter.
- Over five years, Return on Sales peaked at 0.02% in Q1 2021 and troughed at 200639.37% in Q3 2024.
- A 5-year average of 12880.09% and a median of 0.68% in 2022 frame the typical range for Return on Sales.
- The sharpest annual moves came in 2022 and 2024: Return on Sales soared 2525 bps in 2022, then tumbled 20063877 bps in 2024.
- A 5-year view of Return on Sales shows it stood at 0.07% in 2020, then sank by 36487 bps to 25.93% in 2021, then jumped by 97 bps to 0.68% in 2022, then plunged by 6457080 bps to 44035.66% in 2023, then slumped by 356 bps to 200639.37% in 2024.
- Business Quant data shows IKT's Return on Sales at 200639.37% in Q3 2024, 2.39% in Q2 2024, and 1.03% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 0.00% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 0.00% |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 0.00% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -200,639.37% |
| Jun 30, 2024 | -2.39% |
| Mar 31, 2024 | -1.03% |
| Dec 31, 2023 | -44,035.66% |
| Sep 30, 2023 | -0.60% |
| Jun 30, 2023 | -0.53% |
| Mar 31, 2023 | -0.73% |
| Dec 31, 2022 | -0.68% |
| Sep 30, 2022 | -6.16% |
| Jun 30, 2022 | -7.08% |
| Mar 31, 2022 | -1.01% |
| Dec 31, 2021 | -25.93% |
| Sep 30, 2021 | -0.14% |
| Jun 30, 2021 | -0.02% |
| Mar 31, 2021 | -0.02% |
| Dec 31, 2020 | -0.07% |
| Sep 30, 2020 | -0.18% |
| Jun 30, 2020 | -0.02% |
| Mar 31, 2020 | -0.02% |